Randomized, Placebo-Controlled Study of Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Healthy Adult Volunteers

Trial Profile

Randomized, Placebo-Controlled Study of Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs MYK 491 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; First in man
  • Sponsors MyoKardia
  • Most Recent Events

    • 08 Mar 2018 Status changed from recruiting to completed according to a MyoKardia media release.
    • 14 Feb 2018 According to a MyoKardia media release, detail results (n=64) from this study will be present at a future medical meeting.
    • 27 Sep 2017 According to a MyoKardia media release, Based on results observed to date, MyoKardia has elected to include additional dose cohorts in the trial in order to further refine its understanding of MYK-491 pharmacokinetics and pharmacodynamics. Topline data from the 001 trial are now expected to be released by early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top